The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Tumour antibody serum compositions is a key innovation area in immuno-oncology
Serum antibodies play a crucial role in both innate and adaptive immunity and in immunological memory. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker. The production of serum antibodies results from regulated differentiation of B lymphocytes into antibody secreting cells (ASCs), plasma blasts, and plasma cells.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 310+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of tumour antibody serum compositions.
Key players in tumour antibody serum compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to tumour antibody serum compositions
Source: GlobalData Patent Analytics
F. Hoffmann-La Roche Ltd is the leading patent filer in tumour antibody serum compositions. F. Hoffmann-La Roche (Roche) develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases.. Bristol-Myers Squibb and Amgen are among the other key patent filers in tumour antibody serum compositions.
In terms of application diversity, EpimAb Biotherapeutics is the top company, followed by Light Chain Bioscience and MediGene AG. By means of geographic reach, Atara Biotherapeutics Inc holds the top position. Immutep Ltd. and Argenx SE stand in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
